多学科甲胎蛋白异质体临床应用专家共识

摘要/Abstract

中图分类号:

R730.4

上海市医学会分子诊断专科分会, 上海市临床检验中心, 上海东方肝胆外科医院, 中华医学会检验医学分会临床免疫学组, 中国中西医结合检验学会肝病学术委员会, 全军肝胆外科专业委员会, 上海免疫学会肿瘤免疫分会, 上海抗癌协会肿瘤标志物分会. 多学科甲胎蛋白异质体临床应用专家共识[J]. 诊断学理论与实践, 2018, 17(01): 19-24.

[1] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志,2011,16(10):929-946.
[2] Kokudo N,Hasegawa K,Akahane M,et al.Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res,2015,45(2):123-127.
[3] Hoofnagle JH, Doo E, Liang TJ, et al.Management of hepatitis B: summary of a clinical research workshop[J]. Hepatology,2007, 45(4):1056-1075.
[4] Ganem D, Prince AM.Hepatitis B virus infection--natural history and clinical consequences[J]. N Engl J Med,2004, 350(11):1118-1129.
[5] Thein HH, Yi Q, Dore GJ, et al.Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression[J]. Hepatology,2008,48(2):418-431.
[6] El-Serag HB, Rudolph KL.Hepatocellular carcinoma: epidemiology and molecular carcinogenesis[J]. Gastroenterology,2007,132(7):2557-2576.
[7] Sato Y, Nakata K, Kato Y, et al.Early recognition of hepatocellularcarcinoma based on altered profiles of alpha-fetoprotein[J]. N Engl J Med,1993,328(25):1802-1806.
[8] Hu B, Tian X, Sun J, et al.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis[J]. Int J Mol Sci,2013,14(12):23559-23580.
[9] Hadziyannis E, Sialevris K, Georgiou A, et al.Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels[J]. Oncol Rep,2013,29(2):835-839.
[10] Song P, Feng X, Zhang K, et al.Perspectives on using des-γ-carboxyprothrombin(DCP) as a serum biomarker: facilitating early detection of hepatocellularcarcinoma in China[J]. Hepatobiliary SurgNutr,2013,2(4):227-231.
[11] Kumada T, Toyoda H, Tada T, et al.High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma[J]. J Gastroenterol,2014,49(3):555-563.
[12] Tateishi R, Yoshida H, Matsuyama Y, et al.Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review[J]. Hepatol Int,2008,2(1):17-30.
[13] Toyoda H, Kumada T, Tada T.Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma[J]. Oncology,2011,81(Suppl 1):61-65.
[14] Thomas MB, Jaffe D, Choti MM, et al.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting[J]. J ClinOncol,2010,28(25):3994-4005.
[15] Hanaoka T, Sato S, Thbita H, et al.Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease[J]. J GastroenterolHepatol,2011,26(4):739-744.
[16] Volk ML, Hernandez JC, Su GL, et al.Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3[J]. Cancer Biomark,2007,3(2):79-87.
[17] Marrero JA, Feng Z, Wang Y, et al.Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J]. Gastroenterology,2009,137(1):110-118.
[18] 徐万菊, 韩玉刚, 张芊, 等. 甲胎蛋白异质体与高尔基体蛋白73在甲胎蛋白低浓度肝细胞癌诊断中的意义[J]. 中华检验医学杂志,2012,35(2):174-176.
[19] 胡敏华, 陈燕, 梁亚嘉, 等. 新微量离心柱法测定甲胎蛋白异质体对原发性肝癌诊断的价值(附297例分析)[J]. 福建医药杂志,2009,31(4):95-96.
[20] 徐恩君, 陈秋莉, 李涛, 等. 血清AFP、AFP-L3联合检测在原发性肝癌中的诊断价值[J]. 安徽医科大学学报,2016,51(7):1066-1070.
[21] 季君, 顾星, 高致远, 等. 凝集素微量离心柱法检测甲胎蛋白异质体在原发性肝癌中的应用评价[J]. 检验医学,2011,26(4):256-259.
[22] Okuda H, Saito A, Shiratori K, et al.Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3[J]. J Gastroenterol Hepatol,2005,20(5):759-764.
[23] Tada T, Kumada T, Toyoda H, et al.Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma[J]. Liver Int,2005,25(4):848-853.
[24] Okuda H, Nakanishi T, Takatsu K, et al.Clinicopatholo-gic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone[J]. J GastroenterolHepatol,2002,17(7):772-778.
[25] Matsuda M, Asakawa M, Amemjya H, et al.Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC[J]. J GastroenterolHepatol,2011,26(4):731-738.
[26] Saito Y, Shimada M, Utsunomiya T, et al.Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein[J]. Hepatol Res,2012,42(9):887-894.
[27] Kiriyama S, Uchiyama K, Ueno M, et al.Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival[J]. Ann Surg,2011,254(6):984-991.
[28] Nakagawa S, Beppu T, Okabe H, et al.Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma[J]. Hepatol Res,2014,44(9):964-974.
[29] Kobayashi M, Hosaka T, Ikeda K, et al.Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively[J]. Hepatol Res,2011,41:373-379.
[30] Wang FS, Fan JG, Zhang Z, et al.The global burden of liver disease: the major impact of China[J]. Hepatology,2014,60(6):2099-2108.
[31] Fattovich G, Stroffolini T, Zagni I, et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors[J]. Gastroenterology,2004,127:S35-S50.
[32] Okuda H, Shiratori K, Yamamoto M, et al.Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma[J]. J GastroenterolHepatol,2006,21(5):869-873.
[33] Choi J, Park Y, Kimj-H, et al.Evaluation of revisited fucosylated alpha-fetoprotein (AFP-L3) with an autoanalyzer μTAS in a clinical laboratory[J]. Clin Chim Acta,2012,413:170-174.
[34] Kurosawa T, Watanabe M.Development of on-chip fully automated immunoassay system "μTASWako i30" to measure the changes in glycosylation profiles of alpha-fetoprotein in patients with hepatocellular carcinoma[J]. Proteomics,2016,16(24):3056-3061.

多学科甲胎蛋白异质体临床应用专家共识

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价

[1]	何亲羽, 王伟, 陈立芬, 张雪蕾, 董治亚.LHCGR基因突变致家族性男性性早熟2例报告及文献复习[J]. 诊断学理论与实践, 2022, 21(05): 598-605.
[2]	陈志敏, 何浩岚.艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[3]	沈银忠.《人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识》解读[J]. 诊断学理论与实践, 2022, 21(04): 431-436.
[4]	陈宏, 沈银忠.人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[5]	何新, 陈慧, 冯炜炜.机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546.
[6]	徐子真, 李擎天, 刘湘帆, 李莉, 李惠, 王也飞, 吴洁敏, 陈宁, 梁璆荔, 陈松立, 戴健敏, 宋珍, 丁磊.实验诊断学在线课程的建立和实践[J]. 诊断学理论与实践, 2022, 21(04): 547-550.
[7]	赵然, 詹维伟, 侯怡卿.计算机辅助诊断系统辅助超声诊断甲状腺弥漫性病变合并结节良恶性的应用价值[J]. 诊断学理论与实践, 2022, 21(03): 390-394.
[8]	郭业兵, 郑金峰.阴道壁胃肠道外间质瘤一例报道并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 405-407.
[9]	王刚, 陈生弟.神经病学的诊断：起源、发展及挑战[J]. 诊断学理论与实践, 2022, 21(01): 1-4.
[10]	唐静仪, 余群, 刘军.结合人工智能的结构影像分析对阿尔茨海默病的早期预测及精准诊断研究进展[J]. 诊断学理论与实践, 2022, 21(01): 12-17.
[11]	魏文石.直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7.
[12]	王蔚, 王小钦.缺铁性贫血的病因诊断[J]. 诊断学理论与实践, 2021, 20(06): 529-532.
[13]	岳婧婧, 宋琦, 江旭峰, 王黎, 赵维莅, 严福华.磁共振全身扩散加权成像结合T2WI抑脂序列与FDG-PET/CT在初发淋巴瘤分期及病灶检出的对比研究[J]. 诊断学理论与实践, 2021, 20(06): 540-546.
[14]	王昭晖, 吴海波.胃神经鞘瘤31例临床病理学分析[J]. 诊断学理论与实践, 2021, 20(06): 552-556.
[15]	王广宇, 杨昕, 张立娟, 谭姣容.住院新诊断2型糖尿病男性患者血浆总睾酮水平与骨钙素的相关性研究[J]. 诊断学理论与实践, 2021, 20(06): 573-578.